Introduction Powerful changes both in scientific profile and treatment strategy of non ST-segment elevation myocardial infarction (NSTEMI) individuals have been noticed recently. percent (in females from 6.6% to 3.3%; 0.001 and in men AZ 3146 tyrosianse inhibitor from 4.9% to 2.5%; 0.001, respectively). Similarly, 12-month mortality decreased up to one third (in women from 21.6%… Continue reading Introduction Powerful changes both in scientific profile and treatment strategy of non ST-segment elevation myocardial infarction (NSTEMI) individuals have been noticed recently